Lee Seung Bum, Kim Kang Mo, An Jihyun, Lee Danbi, Shim Ju Hyun, Lim Young-Suk, Lee Han Chu, Chung Young-Hwa, Lee Yung Sang
Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Liver Int. 2016 Sep;36(9):1351-61. doi: 10.1111/liv.13099. Epub 2016 Mar 24.
BACKGROUND & AIMS: We investigated potential aetiologies, clinical characteristics and prognosis of non-B non-C (NBNC) hepatocellular carcinoma (HCC) patients in hepatitis B virus (HBV) endemic area, according to potential causes such as previous HBV exposure, chronic alcohol intake and metabolic syndrome.
Among 4690 HCC patients treated at Asan Medical Center between 2007 and 2009, 523 were newly diagnosed with NBNC HCC, and their medical records and survival data were analyzed retrospectively.
Among 321 NBNC HCC patients whose hepatitis B core antibody (anti-HBc) test results were available, 81.0%, 37.1% and 15.5% had anti-HBc positivity, chronic alcohol intake and metabolic syndrome respectively. One-hundred and fifty-two patients (47.4%) had previous exposure to HBV without chronic alcohol intake or metabolic syndrome. Hepatitis B surface antibody (anti-HBs) was positive in 48.0% of the 523 NBNC HCC patients, which was much lower than that in general Korean population, and 52.3% of anti-HBc-positive NBNC HCC patients were negative for anti-HBs. Anti-HBc-negative alcoholic patients presented with more advanced cirrhosis with Child-Pugh class B/C liver function than anti-HBc-positive patients (P = 0.002). In multivariate analysis, baseline liver function, alpha-foetoprotein levels and tumour stage were significant prognostic factors and aetiology did not affect patient survival.
Prior HBV infection could be a potential aetiology in over 40% of NBNC HCC patients in HBV endemic area. Positivity for anti-HBc and negativity for anti-HBs may be a serologic surrogate marker for occult HBV infection in these area. The prognosis of NBNC HCC was determined by tumour stage and underlying liver function.
我们根据既往乙肝病毒(HBV)暴露、长期饮酒和代谢综合征等潜在病因,对HBV流行地区非B非C(NBNC)肝细胞癌(HCC)患者的潜在病因、临床特征及预后进行了研究。
在2007年至2009年间于峨山医学中心接受治疗的4690例HCC患者中,523例新诊断为NBNC HCC,对其病历及生存数据进行回顾性分析。
在321例可获得乙肝核心抗体(抗-HBc)检测结果的NBNC HCC患者中,抗-HBc阳性、长期饮酒和代谢综合征患者分别占81.0%、37.1%和15.5%。152例患者(47.4%)既往有HBV暴露史,但无长期饮酒或代谢综合征。523例NBNC HCC患者中,48.0%的患者乙肝表面抗体(抗-HBs)呈阳性,这一比例远低于韩国普通人群,且抗-HBc阳性的NBNC HCC患者中52.3%抗-HBs呈阴性。抗-HBc阴性的酒精性肝病患者与抗-HBc阳性患者相比,其肝硬化程度更重,肝功能为Child-Pugh B/C级(P = 0.002)。多因素分析显示,基线肝功能、甲胎蛋白水平和肿瘤分期是显著的预后因素,病因不影响患者生存。
既往HBV感染可能是HBV流行地区超过40%的NBNC HCC患者的潜在病因。抗-HBc阳性和抗-HBs阴性可能是这些地区隐匿性HBV感染的血清学替代标志物。NBNC HCC的预后由肿瘤分期和基础肝功能决定。